|
|
|
|
|||||
|
|
|
Cencora, Inc. (NYSE:COR) is included among the 15 Dividend Stocks that Outperform the S&P 500.
On November 11, JPMorgan raised its price target on Cencora, Inc. (NYSE:COR) to $417 from $344 while maintaining an Overweight rating, following an update to the company’s financial model.
On November 5, Cencora, Inc. (NYSE:COR) announced plans to invest $1 billion through 2030 to strengthen its US supply chain, alongside reporting Q4 FY25 results that surpassed Street expectations. The investment responds to growing demand for specialty drugs, including obesity and cancer therapies, which require more complex storage and handling, according to The Wall Street Journal.
For fiscal Q4 2025,Cencora, Inc. (NYSE:COR) posted revenue of $83.7 billion, representing 5.9% growth year over year. During the year, the company advanced several strategic initiatives to reinforce its position in healthcare, including expanding its specialty segment through the acquisition of RCA and strategically refocusing its existing business portfolio. The company also raised its quarterly dividend by 9% to $0.60 per share.
Cencora, Inc. (NYSE:COR) raised its long-term guidance, projecting adjusted operating income growth of 6% to 9% and adjusted EPS growth of 9% to 13%.
Cencora, Inc. (NYSE:COR) is a global pharmaceutical solutions company that distributes medications and provides services supporting the healthcare industry.
While we acknowledge the potential of COR as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 15 High Quality Dividend Stocks for Long-Term Investors and 14 Best Up and Coming Dividend Stocks to Buy.
Disclosure: None.
| 4 hours | |
| 4 hours | |
| 16 hours | |
| Dec-02 | |
| Dec-02 | |
| Dec-01 | |
| Dec-01 | |
| Nov-28 | |
| Nov-26 | |
| Nov-25 | |
| Nov-24 | |
| Nov-21 | |
| Nov-18 | |
| Nov-17 | |
| Nov-14 |
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite